Clinical potential of the ERG oncoprotein in prostate cancer

Nature Reviews Urology

Volumn 9, Issue 3, 2012, Pages 131-137

  Rosen, Philip ^a   Sesterhenn, Isabell A ^b   Brassell, Stephen A ^c   McLeod, David G ^c   Srivastava, Shiv ^a   Dobi, Albert ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Genitourinary Pathology   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9FY; MONOCLONAL ANTIBODY EPR 3864; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; DNA DAMAGE; GENE EXPRESSION; GENE FUSION; GENE REARRANGEMENT; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; COHORT STUDIES; HUMANS; MALE; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858288121     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.10     Document Type: Review

References (78)

1. Siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236 (2011).
2. Ernst, T. et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am. J. Pathol. 160, 2169-2180 (2002). (Pubitemid 34663408)
3. Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young, C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003). (Pubitemid 36917897)
4. Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847-3852 (2005). (Pubitemid 40826884)
5. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
6. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007). (Pubitemid 47206938)
7. Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497-511 (2008).
8. Pflueger, D. et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11, 804-811 (2009).
9. Sreenath, T., Dobi, A., Petrovics, G. & Srivastava, S. Oncogenic activation of ERG: a predominant mechanism in prostate cancer. J. Carcinog. http://dx.doi.org/10.4103/1477-316391122.
10. Rubin, M. A., Maher, C. A. & Chinnaiyan, A. M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 29, 3659-3668 (2011).
11. Clark, J. P. & Cooper, C. S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6, 429-439 (2009).
12. Narod, S. A., Seth, A. & Nam, R. Fusion in the ETS gene family and prostate cancer. Br. J. Cancer 99, 847-851 (2008).
13. Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188 (2008). (Pubitemid 351240884)
14. Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci. USA 105, 2105-2110 (2008). (Pubitemid 351439472)
15. King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
16. Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
17. Zong, Y. et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl Acad. Sci. USA 106, 12465-12470 (2009).
18. Sun, C. et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27, 5348-5353 (2008).
19. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
20. Kunderfranco, P. et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 5, e10547 (2010).
21. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
22. Mohamed, A. A. et al. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol. Ther. 11, 410-417 (2011).
23. Wang, J. et al. Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4. Cancer Res. 71, 1325-1333 (2011).
24. Leshem, O. et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 6, e21650 (2011).
25. Saramaki, O. R. et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 14, 3395-3400 (2008).
26. Winnes, M., Lissbrant, E., Damber, J. E. & Stenman, G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17, 1033-1036 (2007).
27. Gopalan, A. et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 69, 1400-1406 (2009).
28. Dobi, A. et al. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters. The Open Cancer Journal 3, 101-108 (2010).
29. Hermans, K. G. et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66, 10658-10663 (2006). (Pubitemid 44876959)
30. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007). (Pubitemid 46026500)
31. Nam, R. K. et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 97, 1690-1695 (2007). (Pubitemid 350249347)
32. Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596-4599 (2007). (Pubitemid 47037039)
33. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006). (Pubitemid 44449140)
34. Wang, J., Cai, Y., Ren, C. & Ittmann, M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66, 8347-8351 (2006). (Pubitemid 44449142)
35. Rajput, A. B. et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60, 1238-1243 (2007). (Pubitemid 350084545)
36. Tomlins, S. A. et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 56, 275-286 (2009).
37. Bonaccorsi, L. et al. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J. Endocrinol. Invest. 32, 590-596 (2009).
38. Turner, D. P. & Watson, D. K. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev. Anticancer Ther. 8, 33-42 (2008).
39. Reddy, E. S., Rao, V. N. & Papas, T. S. The erg gene: a human gene related to the ets oncogene. Proc. Natl Acad. Sci. USA 84, 6131-6135 (1987). (Pubitemid 17140179)
40. Furusato, B. et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13, 228-237 (2010).
41. Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598 (2010).
42. Mohamed, A. A. et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J. Cancer 1, 197-208 (2010).
43. Hu, Y. et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin. Cancer Res. 14, 4719-4725 (2008).
44. Baltzinger, M., Mager-Heckel, A. M. & Remy, P. Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev. Dyn. 216, 420-433 (1999).
45. Birdsey, G. M. et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111, 3498-3506 (2008).
46. Ellett, F., Kile, B. T. & Lieschke, G. J. The role of the ETS factor erg in zebrafish vasculogenesis. Mech. Dev. 126, 220-229 (2009).
47. Miettinen, M. et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 35, 432-441 (2011).
48. van Leenders, G. J. et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod. Pathol. 24, 1128-1138 (2011).
49. Chaux, A. et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol. 35, 1014-1020 (2011).
50. Falzarano, S. M. et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 459, 441-447 (2011).
51. Minner, S. et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 17, 5878-5888 (2011).
52. Braun, M. et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. http://dx.doi. org/10.1038/pcan.2011. 67.
53. He, H. et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am. J. Surg. Pathol. 35, 608-614 (2011).
54. Yaskiv, O. et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am. J. Surg. Pathol. 35, 1062-1068 (2011).
55. Scheble, V. J. et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 23, 1061-1067 (2010).
56. Marcucci, G. et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J. Clin. Oncol. 23, 9234-9242 (2005).
57. Kong, X. T. et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 90, 1192-1199 (1997).
58. Baldus, C. D. et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc. Natl Acad. Sci. USA 101, 3915-3920 (2004). (Pubitemid 38381077)
59. Falzarano, S. M. et al. Single focus prostate cancer: pathological features and ERG fusion status. J. Urol. 185, 489-494 (2011).
60. Mosquera, J. M. et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 14, 3380-3385 (2008).
61. Lotan, T. L. et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24, 820-828 (2011).
62. Cerveira, N. et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826-832 (2006). (Pubitemid 44564838)
63. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882-888 (2007). (Pubitemid 47165141)
64. Clark, J. et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27, 1993-2003 (2008). (Pubitemid 351442741)
65. Braun, M., Menon, R., Nikolov, P. & Perner, S. ERG rearrangement as a clonal expansion marker for prostate cancer. The Open Prostate Cancer Journal 3, 63-68 (2010).
66. Han, B. et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 22, 1083-1093 (2009).
67. Iljin, K. et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66, 10242-10246 (2006). (Pubitemid 44799738)
68. Wang, J. et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 68, 8516-8524 (2008).
69. Koh, C. M. et al. MYC and prostate cancer. Genes Cancer 1, 617-628 (2010).
70. Washington, M. N. & Weigel, N. L. 1{alpha}, 25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 151, 1409-1417 (2010).
71. Wolf, I. et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66, 7818-7823 (2006). (Pubitemid 44289243)
72. Myung, S. J. et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA 103, 12098-12102 (2006).
73. Martin, S. K. & Kyprianou, N. Gene fusions find an ERG-way to tumor inflammation. Cancer Biol. Ther. 11, 418-420 (2011).
74. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668-675 (2010).
75. Epstein, J. I. & Herawi, M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J. Urol. 175, 820-834 (2006). (Pubitemid 43199991)
76. Bismar, T. A. et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 107, 477-485 (2011).
77. Yoshimoto, M. et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 21, 1451-1460 (2008).
78. Reid, A. H. et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 102, 678-684 (2010).